Approval Package for:

APPLICATION NUMBER:

20-702/S027

Trade Name: Lipitor Tablets

Generic Name: atorvastatin calcium

Sponsor: Pfizer Pharmaceuticals

Approval Date: May 24, 2004
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
20-702/S027

CONTENTS

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Document Description</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td>X</td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
20-702/S027

APPROVAL LETTER
NDA 20-702/S-027

Pfizer Inc., US Agent for
Pfizer Ireland Pharmaceuticals
Attention: Madeleine M. Jester
Director, US Regulatory Affairs
235 East 42nd Street
New York, NY 10017

Dear Ms. Jester:

Please refer to your supplemental new drug application dated June 20, 2001, received June 21, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lipitor (Atorvastatin calcium) tablets.


This supplemental new drug application proposes to implement a Patient Package Insert (PPI) for Lipitor.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted draft labeling (patient package insert submitted May 14, 2004)(copy enclosed).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-702/S-027." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the patient package insert directly to:
Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

(See appended electronic signature page)

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Parks
5/24/04 08:40:10 AM
NDA 20-702/S-027

Pfizer Inc.
Attention: Christopher A. Graham
Associate Director, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Mr. Graham:

Please refer to your supplemental new drug application dated June 20, 2001, received June 21, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lipitor (Atorvastatin calcium) tablets.

We acknowledge receipt of your submission dated August 17, 2001. This supplement proposes to implement a Patient Package Insert (PPI) for Lipitor.

Additionally, we refer to our June 5, 2002, fax which provided labeling comments on your proposed PPI.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, however, it will be necessary for you to submit draft labeling incorporating the revisions recommended in our fax of June 5, 2002. These comments are enclosed with this letter.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

This product may be considered to be misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with these changes prior to approval of this supplemental application.
If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

[See appended electronic signature page]

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Parks
8/8/02 09:14:36 AM
for Dr. Orloff
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
20-702/S027

LABELING
PATIENT INFORMATION

LIPITOR
atorvastatin calcium tablets
(LIP-i-tore)

Read the Patient Information that comes with LIPITOR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.

If you have any questions about LIPITOR, ask your doctor or pharmacist.

What is LIPITOR?
LIPITOR is a prescription medicine that lowers cholesterol in your blood. It lowers the "bad" cholesterol and triglycerides in your blood. It can raise your "good" cholesterol as well. LIPITOR is for adults and children over 10 whose cholesterol does not come down enough with exercise and a low-fat diet alone. LIPITOR starts to work in about 2 weeks.

What is Cholesterol?
Cholesterol and triglycerides are fats that are made in your body. They are also found in foods. You need some cholesterol for good health, but too much is not good for you. Cholesterol and triglycerides can clog your blood vessels. It is especially important to lower your cholesterol if you have heart disease, smoke, have diabetes or high blood pressure, are older, or if heart disease starts early in your family.

Who Should Not Take LIPITOR?
Do not take LIPITOR if you:
• are allergic to LIPITOR or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in LIPITOR.
• LIPITOR has not been studied in children under 10 years of age.

Before You Start LIPITOR
Tell your doctor if you:
• have muscle aches or weakness
• drink more than 2 glasses of alcohol daily
• have diabetes
• have a thyroid problem
• have kidney problems

Some medicines should not be taken with LIPITOR. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for:
• your immune system
• cholesterol
• infections
• birth control
• heart failure
• HIV or AIDS

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.

How Should I Take LIPITOR?
• Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.
• Take LIPITOR each day at any time of day at about the same time each day. LIPITOR can be taken with or without food.

Don't break LIPITOR tablets before taking.

• Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.
• If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.
• If you take too much LIPITOR or overdose, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.

What Should I Avoid While Taking LIPITOR?
• Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.
• Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?
LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include:
• Muscle problems. LIPITOR can cause serious muscle problems that can lead to kidney problems, including kidney failure. You have a higher chance for muscle problems if you are taking certain other medicines with LIPITOR.
• Liver problems. LIPITOR can cause liver problems. Your doctor may do blood tests to check your liver before you start taking LIPITOR, and while you take it.

Call your doctor right away if you have:

Rev. November 18, 2003
• muscle problems like weakness, tenderness, or pain that happen without a good reason, especially if you also have a fever or feel more tired than usual
• nausea and vomiting
• passing brown or dark-colored urine
• you feel more tired than usual
• your skin and whites of your eyes get yellow
• stomach pain

Common side effects of LIPITOR include headache, constipation, diarrhea, gas, upset stomach and stomach pain, rash, and muscle and joint pain. These side effects are usually mild and may go away.

Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.

These are not all the side effects of LIPITOR. Ask your doctor or pharmacist for a complete list.

How do I store Lipitor?

• Store LIPITOR at room temperature, 68 to 77°F (20 to 25°C).
• Do not keep medicine that is out of date or that you no longer need.
• Keep LIPITOR and all medicines out of the reach of children. Be sure that if you throw medicine away, it is out of the reach of children.

General Information About LIPITOR

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LIPITOR for a condition for which it was not prescribed. Do not give LIPITOR to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about LIPITOR. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LIPITOR that is written for health professionals. Or you can go to the LIPITOR website at www.lipitor.com.

What are the ingredients in LIPITOR?

Active Ingredient: atorvastatin calcium

Inactive Ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.

Rx Only

Manufactured by Pfizer Ireland Pharmaceuticals
Dublin, Ireland
Distributed by Parke-Davis, Division of Pfizer Inc
New York, NY 10017 USA
© 2003 Pfizer Ireland Pharmaceuticals
All rights reserved.
May 2004
23-6026-00-0

Rev. November 18, 2003
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
20-702/S027

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
Memo to File

NDA #: 20-702/S027
Drug name: Lipitor (atorvastatin)
Sponsor: Pfizer
Date of Submission: May 14, 2004
Document: SLR/Seq 027/MOD BL

This memo addresses the Patient Package Insert (PPI) for atorvastatin submitted to the Agency on May 14, 2004, received May 17, 2004. This PPI has been reviewed by this medical officer and reviewers in DDMAC and DSRS. It was deemed acceptable and this supplement should therefore be approved.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Mary Parks
5/21/04 11:16:56 AM
MEDICAL OFFICER
MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: January 16, 2004

TO: David Orloff, M.D., Director
Division of Metabolic and Endocrine Drug Products
HFD-510

VIA: Margaret Simoneau, R.Ph., Regulatory Health Project Manager,
Division of Metabolic and Endocrine Drug Products
HFD-510

FROM: Jeanine Best, M.S.N., R.N., P.N.P.
Patient Product Information Specialist
Division of Surveillance, Research, and Communication Support
HFD-410

THROUGH: Gerald DalPan, M.D., M.H.S., Director
Division of Surveillance, Research, and Communication Support
HFD-410

SUBJECT: ODS/DSRCS Review of the Patient Labeling for Lipitor
(atorvastatin calcium) tablets, NDA 20-702/S-027

The attached patient labeling (clean copies) represent the revised risk communication materials
for Lipitor (atorvastatin) tablets, NDA 20-702/S-027. It has been reviewed by our office and by
DDMAC. We have simplified the wording, made it consistent with the PI, removed promotional
language and other unnecessary information (the purpose of patient information leaflets is to
enhance appropriate use and provide important risk information about medications), and put it in
the format that we are recommending for all patient information. Our proposed changes are
known through research and experience to improve risk communication to a broad audience of
varying educational backgrounds. These revisions are based on draft labeling submitted by the
sponsor on November 21, 2003. Patient information should always be consistent with the
prescribing information. All future changes to the PI should also be reflected in the PPI.

Comments to the review division are bolded, underlined and italicized. We can provide marked-
up and clean copies of the revised documents in Word if requested by the review division.
Please call is if you have any questions

PATIENT INFORMATION
Read the Patient Information that comes with LIPITOR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment. If you have any questions about LIPITOR, ask your doctor or pharmacist.

**What is LIPITOR?**

LIPITOR is a prescription medicine that lowers cholesterol in your blood. It lowers the "bad" cholesterol and triglycerides in your blood. It can raise your "good" cholesterol as well. LIPITOR is whose cholesterol does not come down enough with exercise and a low-fat diet alone. LIPITOR starts to work in about 2 weeks.

**What is Cholesterol?**

Cholesterol and triglycerides are fats that are made in your body. They are also found in foods. You need some cholesterol for good health, but too much is not good for you. Cholesterol and triglycerides can clog your blood vessels. It is especially important or if heart disease starts early in your family.

**Who Should Not Take LIPITOR?**

Do not take LIPITOR if you:

- are pregnant or think you may be pregnant, or are planning to become pregnant. LIPITOR may harm your unborn baby. If you get pregnant, stop taking LIPITOR and call your doctor right away.
- are breast feeding. LIPITOR can pass into your breast milk and may harm your baby.
- have liver problems
- are allergic to LIPITOR or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in LIPITOR.

LIPITOR has not been studied in children under 10 years of age.

**Before You Start LIPITOR**

Tell your doctor if you:

- have muscle aches or weakness
- drink a lot of alcohol
- have diabetes
- have a thyroid problem
- have kidney problems

Some medicines should not be taken with LIPITOR. Tell your doctor about all the medicines
you take, including prescription and non-prescription medicines, vitamins and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for:
- your immune system
- cholesterol
- infections
- birth control
- heart failure
- HIV or AIDS

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.

**How Should I Take LIPITOR?**

- Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.
- Take LIPITOR with or without food.
- Don't break LIPITOR tablets before taking.

**What Should I Avoid While Taking LIPITOR?**

- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins and herbal supplement. LIPITOR and certain other medicines can interact causing serious side effects.
- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

**What are the Possible Side Effects of LIPITOR?**

[DSRCS Comment: List serious SEs first.]
LIPITOR can cause serious side effects. **DDMAC Comment: DDMAC recommends because it minimizes the risk information and can be used promotionally to minimize the risk information.**

- **Muscle**. LIPITOR can cause serious muscle that can lead to kidney. You have a higher chance for muscle if you are taking certain other medicines with LIPITOR.
- **Liver**. LIPITOR can cause liver. Your doctor may do blood tests to check your liver before you start taking LIPITOR, and while you take it.

**Call your doctor right away if you have:**
- muscle problems like weakness, tenderness, or pain that don’t have happen for a good reason, especially if you also have a fever or feel more tired than usual
- nausea and vomiting
- passing brown or dark-colored urine
- you feel more tired than usual
- your skin and whites of your eyes get yellow
- stomach pain

**Common side effects** of LIPITOR include headache, constipation, diarrhea, gas, upset stomach and stomach pain, rash, and muscle and joint pain. These side effects are usually mild away.

Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.

These are not all the side effects of LIPITOR. Ask your doctor or pharmacist for a complete list.

**How do I store Lipitor?**
- Store LIPITOR at room temperature, 68 to 77°F (20 to 25°C).
- Do not keep medicine that is out of date or that you no longer need.
- **Keep LIPITOR and all medicines out of the reach of children.** Be sure that if you throw medicine away, it is out of the reach of children.

**General information about LIPITOR**
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LIPITOR for a condition for which it was not prescribed. Do not give LIPITOR to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about LIPITOR. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LIPITOR that is written for health professionals. Or you can go to the LIPITOR website at [www.lipitor.com](http://www.lipitor.com).

**What are the ingredients in LIPITOR?**
Active Ingredient: atorvastatin calcium
Inactive Ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.

Rx Only

Manufactured by Pfizer Ireland Pharmaceuticals
Dublin, Ireland
Distributed by Parke-Davis, Division of Pfizer Inc
New York, NY 10017 USA
© 2001 Pfizer Ireland Pharmaceuticals
All rights reserved.
Printed in USA/ May 2001
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jeanine Best
1/16/04 08:44:26 AM
DRUG SAFETY OFFICE REVIEWER

Toni Piazza Hepp
1/16/04 03:40:03 PM
DRUG SAFETY OFFICE REVIEWER
for Gerald Dal Pan
DATE: March 2, 2004

<table>
<thead>
<tr>
<th>To:</th>
<th>Madeleine M. Jester</th>
</tr>
</thead>
<tbody>
<tr>
<td>From:</td>
<td>Margaret Simoneau</td>
</tr>
<tr>
<td>Company:</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td></td>
<td>Division of Metabolic and Endocrine Drug Products</td>
</tr>
<tr>
<td>Fax number:</td>
<td>212-857-3558</td>
</tr>
<tr>
<td></td>
<td>Fax number: 301-443-9282</td>
</tr>
<tr>
<td>Phone number:</td>
<td>212-733-5843</td>
</tr>
<tr>
<td></td>
<td>Phone number: (301) 827-6411</td>
</tr>
<tr>
<td>Subject:</td>
<td>NDA 20-702/S-027</td>
</tr>
</tbody>
</table>

Total no. of pages including cover: 3

Comments:

Document to be mailed: • YES ☑ NO

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If you are not the addressee, or a person authorized to deliver this document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us immediately by telephone at (301) 827-6430. Thank you.
PATIENT INFORMATION

LIPITOR®
atorvastatin calcium tablets

[DSRCS Comment: Add the phonetic spelling (LIP-in-tore) next to the tradename in the heading.]

Read the Patient Information that comes with LIPITOR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.

If you have any questions about LIPITOR, ask your doctor or pharmacist.

What is LIPITOR?
LIPITOR is a prescription medicine that lowers cholesterol in your blood. It lowers the "bad" cholesterol and triglycerides in your blood. It can raise your "good" cholesterol as well.
LIPITOR is the brand name for atorvastatin, whose cholesterol does not come down enough with exercise and a low-fat diet alone. LIPITOR starts to work in about 2 weeks.

What is Cholesterol?
Cholesterol and triglycerides are fats that are made in your body. They are also found in foods. You need some cholesterol for good health, but too much is not good for you. Cholesterol and triglycerides can clog your blood vessels. It is especially important to lower your cholesterol if you have heart disease or if heart disease starts early in your family.

Who Should Not Take LIPITOR?
Do not take LIPITOR if you:
- are pregnant or think you may be pregnant, or are planning to become pregnant. LIPITOR may harm your unborn baby. If you get pregnant, stop taking LIPITOR and call your doctor right away.
- are breast feeding. LIPITOR can pass into your breast milk and may harm your baby

- have liver problems
- are allergic to LIPITOR or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in LIPITOR.
LIPITOR has not been studied in children under 10 years of age.

Before You Start LIPITOR
Tell your doctor if you:
- have muscle aches or weakness
- drink more than 2 glasses of alcohol daily
- have diabetes
- have a thyroid problem
- have kidney problems

Some medicines should not be taken with LIPITOR. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for:
- your immune system
- cholesterol
- infections
- birth control
- heart failure
- HIV or AIDS

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.

How Should I Take LIPITOR?

- Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.
- Take LIPITOR. LIPITOR can be taken with or without food.
- Don't break LIPITOR tablets before taking. DSRCS Comment:
- Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.
- If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.
- If you take too much LIPITOR or overdose, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.

What Should I Avoid While Taking LIPITOR?

- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins and herbal supplement. LIPITOR and certain other medicines can interact causing serious side effects.
- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?

DSRCS Comment: List serious SEs first.

LIPITOR can cause serious side effects, including: DDMAC Comment: DDMAC recommends because it minimizes the risk information and
can be used promotionally to minimize the risk information.

- **Muscle** LIPITOR can cause serious muscle that can lead to kidney. You have a higher chance for muscle if you are taking certain other medicines with LIPITOR.
- **Liver** LIPITOR can cause liver damage. Your doctor may do blood tests to check your liver before you start taking LIPITOR, and while you take it.

**Call your doctor right away if you have:**

- muscle problems like weakness, tenderness, or pain that happen without a good reason, especially if you also have a fever or feel more tired than usual
- nausea and vomiting
- passing brown or dark-colored urine
- you feel more tired than usual
- your skin and whites of your eyes get yellow
- stomach pain

**Common side effects of LIPITOR** include headache, constipation, diarrhea, gas, upset stomach and stomach pain, rash, and muscle and joint pain. These side effects are usually mild and go away.

Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.

These are not all the side effects of LIPITOR. Ask your doctor or pharmacist for a complete list.

- Store LIPITOR at room temperature, 68 to 77°F (20 to 25°C).
- Do not keep medicine that is out of date or that you no longer need.
- **Keep LIPITOR and all medicines out of the reach of children.** Be sure that if you throw medicine away, it is out of the reach of children.

**General Information About LIPITOR**

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LIPITOR for a condition for which it was not prescribed. Do not give LIPITOR to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about LIPITOR. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LIPITOR that is written for health professionals. Or you can go to the LIPITOR website at www.lipitor.com.

**What are the ingredients in LIPITOR?**

**Active Ingredient:** atorvastatin calcium

**Inactive Ingredients:** calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.

**Rx Only**

Manufactured by Pfizer Ireland Pharmaceuticals
Dublin, Ireland

Distributed by Parke-Davis, Division of Pfizer Inc
New York, NY 10017 USA

© 2001 Pfizer Ireland Pharmaceuticals
All rights reserved.
Printed in USA/ May 2001
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
____________________
Margaret Simoneau
3/2/04 10:57:04 AM
CSO
NDA 20-702/S-027

PRIOR APPROVAL SUPPLEMENT

Pfizer Inc., Agent for Pfizer Ireland Pharmaceuticals
Attention: Rita A. Wittich
Vice President, Worldwide Regulatory Strategy
235 East 42nd Street, 150/7/12
New York, NY 10017

Dear Ms. Wittich:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Lipitor (atorvastatin calcium) Tablets

NDA Number: 20-702

NDA Number: Pfizer Ireland Pharmaceuticals

Supplement Number: S-027

Date of Supplement: June 20, 2001

Date of Receipt: June 21, 2001

This supplement proposes to implement a Patient Package Insert (PPI) for Lipitor Tablets for the treatment of dyslipidemia.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on August 20, 2001, in accordance with 21 CFR 314.101(a).
Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

**U.S. Postal Service/Courier/Overnight Mail:**

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Metabolic and Endocrine Drug Products, HFD-510  
Attention: Division Document Room, 14B-19  
5600 Fishers Lane  
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-6411.

Sincerely,

*(See appended electronic signature page)*

Margaret Simeneau, R.Ph.  
Regulatory Project Manager  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Margaret Simoneau
7/17/01 10:50:49 AM
REQUEST FOR CONSULTATION

TO (Division/Office):
Karen Lechter, J.D., Ph.D. (7-3898) DDMAC

FROM:
Margaret Simoneau, R.Ph. (7-6411)/HFD-510

DATE: June 29, 2001
IND NO.:
NDA NO.: 20-702/S-027
TYPE OF DOCUMENT: SLR
DATE OF DOCUMENT: June 20, 2001

NAME OF DRUG:
Lipitor (atorvastatin) tablets
PRIORITY CONSIDERATION:
Regulatory 6-month clock
CLASSIFICATION OF DRUG:
Lipid altering agent (statin)
DESIRED COMPLETION DATE:
October 31, 2001

NAME OF FIRM:

REASON FOR REQUEST

I. GENERAL

☐ NEW PROTOCOL
☐ PROGRESS REPORT
☐ NEW CORRESPONDENCE
☐ DRUG ADVERTISING
☐ ADVERSE REACTION REPORT
☐ MANUFACTURING CHANGE/ADDITION
☐ MEETING PLANNED BY
☐ PRE-NDA MEETING
☐ END OF PHASE II MEETING
☐ RESUBMISSION
☐ SAFETY/EFFICACY
☐ PAPER-NDA
☐ CONTROL SUPPLEMENT
☐ RESPONSE TO DEFICIENCY LETTER
☐ FINAL PRINTED LABELING
☐ LABELING REVISION
☐ ORIGINAL NEW CORRESPONDENCE
☐ FORMULATIVE REVIEW
☐ OTHER (SPECIFY BELOW):

II. BIOMETRICS

STATISTICAL EVALUATION BRANCH
☐ TYPE A OR B NDA REVIEW
☐ END OF PHASE II MEETING
☐ CONTROLLED STUDIES
☐ PROTOCOL REVIEW
☐ OTHER (SPECIFY BELOW):

STATISTICAL APPLICATION BRANCH
☐ CHEMISTRY REVIEW
☐ PHARMACOLOGY
☐ BIOPHARMACEUTICS
☐ OTHER (SPECIFY BELOW):

III. BIOPHARMACEUTICS

☐ DISSOLUTION
☐ BIOAVAILABILITY STUDIES
☐ PHASE IV STUDIES
☐ DEFICIENCY LETTER RESPONSE
☐ PROTOCOL-BIOPHARMACEUTICS
☐ IN-VIVO WAIVER REQUEST

IV. DRUG EXPERIENCE

☐ PHASE IV SURVEILLANCE/EPIDEMIOLOGY PROTOCOL
☐ DRUG USE e.g. POPULATION EXPOSURE, ASSOCIATED DIAGNOSES
☐ CASE REPORTS OF SPECIFIC REACTIONS (List below)
☐ COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP
☐ REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY
☐ SUMMARY OF ADVERSE EXPERIENCE
☐ POISON RISK ANALYSIS

V. SCIENTIFIC INVESTIGATIONS

☐ CLINICAL
☐ PRECLINICAL

COMMENTS/SPECIAL INSTRUCTIONS:

Please review the enclosed submission for a Patient Package Insert (PPI) for Lipitor tablets for the treatment of dyslipidemia.

SIGNATURE OF REQUESTER
Dr. David G. Orloff, Division Director, HFD-510

METHOD OF DELIVERY (Check one)
☐ MAIL
☐ HAND

SIGNATURE OF RECEIVER
SIGNATURE OF DELIVERER Margaret Simoneau
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-------------------

David Orloff
7/12/01 06:21:40 PM
REQUEST FOR CONSULTATION

TO (Division/Office):
Mail: Office of Drug Safety (ODS) DSRCs
HFD-410/ Attn: Karen Lechter (7-3241)

FROM:
Margaret Simoneau, R.Ph. (7-6411)/HFD-510

DATE
December 3, 2003

IND. NO.

NDA NO.
20-702

TYPE OF DOCUMENT
SLR (Re-submit)

DATE OF DOCUMENT
November 21, 2003 (in EDR)

NAME OF DRUG
Lipitor (atorvastatin) tablets

PRIORITY CONSIDERATION
Standard

CLASSIFICATION OF DRUG
Lipid altering agent (statin)

DESIRED COMPLETION DATE
February 3, 2003

NAME OF FIRM:

REASON FOR REQUEST

I. GENERAL

- NEW PROTOCOL
- PROGRESS REPORT
- NEW CORRESPONDENCE
- DRUG ADVERTISING
- ADVERSE REACTION REPORT
- MANUFACTURING CHANGE/ADDITION
- MEETING PLANNED BY
- PRE-NDA MEETING
- END OF PHASE II MEETING
- RESUBMISSION
- SAFETY/EFFICACY
- PAPER NDA
- CONTROL SUPPLEMENT
- RESPONSE TO DEFICIENCY LETTER
- FINAL PRINTED LABELING
- LABELING REVISION
- ORIGINAL NEW CORRESPONDENCE
- FORMULATIVE REVIEW
- OTHER (SPECIFY BELOW):

II. BIOMETRICS

STATISTICAL EVALUATION BRANCH
- TYPE A OR B NDA REVIEW
- END OF PHASE II MEETING
- CONTROLLED STUDIES
- PROTOCOL REVIEW
- OTHER (SPECIFY BELOW):

STATISTICAL APPLICATION BRANCH
- CHEMISTRY REVIEW
- PHARMACOLOGY
- BIOPHARMACEUTICS
- OTHER (SPECIFY BELOW):

III. BIOPHARMACEUTICS

- DISSOLUTION
- BIOAVAILABILITY STUDIES
- PHASE IV STUDIES

- DEFICIENCY LETTER RESPONSE
- PROTOCOL-BIOPHARMACEUTICS
- IN-VIVO WAIVER REQUEST

IV. DRUG EXPERIENCE

- PHASE IV SURVEILLANCE/EPIEMIOLOGY PROTOCOL
- DRUG USE e.g. POPULATION EXPOSURE, ASSOCIATED DIAGNOSES
- CASE REPORTS OF SPECIFIC REACTIONS (List below)
- COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP

- REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY
- SUMMARY OF ADVERSE EXPERIENCE
- POISON RISK ANALYSIS

V. SCIENTIFIC INVESTIGATIONS

- CLINICAL
- PRECLINICAL

COMMENTS/SPECIAL INSTRUCTIONS:

Request review of the November 21, 2003, submission regarding the Patient Package Insert for Lipitor. Please feel free to speak with Dr. Mary Parks, Deputy Director and Medical Team Leader, regarding this consult @ 7-6431.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Mary Parks
12/5/03 01:46:10 PM